Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:02 AM
Ignite Modification Date:
2025-12-25 @ 12:02 AM
NCT ID:
NCT05849558
Brief Summary:
This study aims to compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients
Detailed Description:
Research Question:
Compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated chronic liver diseased patients
Primary Objective:
To assess the efficacy of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250mg alone and versus Placebo in the reduction of total serum bilirubin, Direct serum bilirubin and elevated liver Enzymes from baseline to End of Treatment (EOT)
Secondary Objectives:
* To assess the efficacy of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo in reducing the degree of steatosis as measured by Vibration-controlled transient elastography with Controlled Attenuation Parameter (CAP)
* To assess the safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo among compensated Chronic Liver Diseased Patients
* To describe improvement in quality of life for patients after treatment
A study population of 297 patients suffering from compensated chronic Liver Disease, who will be randomized according to Vibration-controlled transient elastography in screening visit into 2 groups:
* Group 1: with non-cirrhosis, F0, F1 and F2.
* Group 2: with advanced fibrosis and cirrhosis, F3 and F4.
Each group will receive either Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg), or UDCA alone or Placebo, through Stratified random sampling.
Duration for enrollment: 6 months Total duration of the study/subject will be approximately: 6 months for treatment and follow-up visits including the screening visit
Subjects will be enrolled for a duration of 6 months including the screening visit
* Screening visit 1 (Treatment initiation)
* Visit 2: after 1st month, follow-up 1
* Visit 3: after 2nd month, follow-up 2
* Visit 4: after 3rd month, follow-up 3
* Visit 5: after 4th month, follow-up 4
* Visit 6: after 5th month, follow-up 5
* End of Study visit, after 6th month of treatment, follow-up 6
Study:
NCT05849558
Study Brief:
Protocol Section:
NCT05849558